Insulin resistance and arteriosclerosis obliterans in patients with NIDDM

Diabetes Care

Volumn 20, Issue 11, 1997, Pages 1738-1743

  Matsumoto, Kazunari ^a,c   Miyake, Seibei ^a   Yano, Mayumi ^a   Ueki, Yukitaka ^b   Yamaguchi, Yoshihiko ^b   Akazawa, Shoichi ^b   Tominaga, Yuko ^b  

^a Sasebo Chuou Hospital   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Sasebo Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; INSULIN; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0030777648     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.11.1738     Document Type: Article

References (38)

1. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141,1979
2. Welbom TA, Weame K: Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care 2:154-160,1979
3. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G: Relationship of plasma insulin level to the incidence of myocardial infarction and coronary heart disease mortality in middle-aged population. Diabetologia 19:205-210,1980
4. DespresJP, Lamaeche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ: Hyperinsulinemia as an independent risk factor for ischémie heart disease. N Engl J Med 334:952-957,1996
5. Laakso M, Sarlund H, Salonen R, Suhonen M, Pyörälä K, Salonen JT, Karhapaa P: Asymptomatic atherosclerosis and insulin resistance. Arteriosder Thromb 11:10681076, 1991
6. Shinozaki K, Naritomi H, Shimizu T, Suzuki M, Ikebuchi M, Sawada T, Harano Y: Role of insulin resistance associated with compensatory hyperinsulinemia in ischémie stroke. Stroke 27:37-43,1996
7. Rossetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-630, 1990
8. Matsumoto K, Akazawa S, Abiru N, Yano M, Ishibashi M, Uotani S, Matsuo H, Kawasaki E, Yamasaki H, Yamamoto H, Yamaguchi Y, Nagataki S: Insulin response after treatment depends on fasting plasma glucose level in NIDDM. Diabetes Res C!in Pract 26:129-135, 1994
9. Ludvik B, NolanJJ, BalogaJ, Sacks D, Olefskyj: Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 44:1121-1125,1995
10. Inchiostro S, Bertoli G, Zanette G, Donadon V: Evidence of higher insulin resistance in NIDDM patients with ischémie heart disease. Diabetologia 37:597-603,1994
11. Utermann G: The mysteries of lipoprotein (a). Science 246:904-910,1989
12. Scanu AM, Fless GM: Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 85:1709-1715,1990
13. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D: Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 38:711-714, 1995
14. World Health Organization: Diabetes Meüitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser, no. 727)
15. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, Corgnati A, Muggeo M: Estimates of in vivo insulin action in man: Comparison of insulin tolerance tests with euglycemic and hyperglycémie glucose clamp studies. J C!in Endocrine! Metab 68:374-378, 1989
16. Akinmokun A, Selby PL, Ramaiya K, Alberti KGMM: The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycemic clamp. Diabet Med 9:432-437,1992
17. Young RP, Critchley JAJH, Anderson PJ, Lau MS, Lee KK, Chan JC: The short insulin tolerance test: feasibility study using venous sampling. Diabet Med 13:429-433, 1996
18. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dislipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
19. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
20. Ross R, Agius L: The process of atherogenesis: cellular and molecular interaction: from experimental animal models to humans. Diabetoîogia 35 (Suppl. 2):S34S40,1992
21. Uno H, Ueki Y, Murashima J, Miyaké S, Tominaga Y, Eguchi K, Yano K: Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerotic obliterans. Atherosclerosis 116:93-102,1995
22. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidermal 137:959-965, 1993
23. DeFronzo RA: The triumvirate: -cell, muscle, liver. Diabetes 37:667-687,1988
24. Chen M, Bergman RN, Pacini G, Porte D: Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased -cell function. J Clin Endocrinol Metab 60:13-20,1985
25. Garvey WT, OlefskyJM, Griffin J, Hamman RF Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234, 1985
26. Bergman RN, Ider YZ, Bowden CR, Cobelli C: Quantitative estimation of insulin sensi-tivity. Am J Physiol 236:E667-E677,1979
27. Bergman RN: Toward physiological understanding of glucose tolerance: minimal model approach. Diabetes 38:1512-1527, 1989
28. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JY Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. Circulation 93:1809-1817,1996
29. Taegtmeyer H: Insulin resistance and atherosclerosis: common roots for two common diseases? Circulation 93:1777-1779, 1996
30. Harano Y, Kojima H, Kosugi K, Suzuki M, Harada M, Nakano T, Hidaka H, Kashiwagi A, Toni R, Taniguchi Y, Nishimori T, Yasuda Y, Shigeta Y: Hyperlipidemia and atherosclerosis in experimental insulinopenic diabetic monkeys. Diabetes Res Clin Pract 16:163-173,1992
31. Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Risk factors predicting lower extremity amputations in patients with NIDDM. Diabetes Care 19:607-612,1996
32. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM: Insulin resistance and cigarette smoking. Lancet 339:1128-1130,1992
33. Rhoads GG, Dahlen G, Berg K, Morion NE, Dannenberg AL: Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256:2540-2544,1986
34. Durrington PN, Ishola M, Arrol S, Bhatgnar D: Apolipoprotein (a), AI and B and parental history in men with early onset ischémie heart disease. Lancet i:10701073,1988
35. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G: Relation of serum lipoprotein (a) and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322:1494-1499,1990
36. Schaeffer EJ, Fava SL, Jenner JL, McNamura JR, OrdovasJM, Davis CE, Abolafia JM, Lippel K, Levy RI: Lipoprotein (a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 271:999-1003, 1994
37. Wood PD, Stefanick ML, Dreon DM, FreyHewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM, Ellsworth NM, Terry RB, Haskell WL: Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. NEnglJMed 319:1173-1179,1988
38. Yao JST: Haemodynamic studies in peripheral arterial disease. BrJSurg 57:761-766, 1970